These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23296546)

  • 41. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A minimally invasive treatment option for large metastatic brain tumors: long-term results of two-session Gamma Knife stereotactic radiosurgery.
    Yomo S; Hayashi M
    Radiat Oncol; 2014 Jun; 9():132. PubMed ID: 24917309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
    Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.
    Strasser-Weippl K; Horick N; Smith IE; O'Shaughnessy J; Ejlertsen B; Boyle F; Buzdar AU; Fumoleau P; Gradishar W; Martin M; Moy B; Piccart-Gebhart M; Pritchard KI; Lindquist D; Rappold E; Finkelstein DM; Goss PE
    Eur J Cancer; 2016 Mar; 56():85-92. PubMed ID: 26829011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is stereotactic radiosurgery a rational treatment option for brain metastases from small cell lung cancer? A retrospective analysis of 70 consecutive patients.
    Yomo S; Hayashi M
    BMC Cancer; 2015 Mar; 15():95. PubMed ID: 25879433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of preexisting tumor necrosis on the efficacy of stereotactic radiosurgery in the treatment of brain metastases in women with breast cancer.
    Xu Z; Marko NF; Angelov L; Barnett GH; Chao ST; Vogelbaum MA; Suh JH; Weil RJ
    Cancer; 2012 Mar; 118(5):1323-33. PubMed ID: 22009460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Breast cancer brain metastases - A 12 year review of treatment outcomes.
    De Ieso PB; Schick U; Rosenfelder N; Mohammed K; Ross GM
    Breast; 2015 Aug; 24(4):426-33. PubMed ID: 25881974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new grading system focusing on neurological outcomes for brain metastases treated with stereotactic radiosurgery: the modified Basic Score for Brain Metastases.
    Serizawa T; Higuchi Y; Nagano O; Matsuda S; Ono J; Saeki N; Hirai T; Miyakawa A; Shibamoto Y
    J Neurosurg; 2014 Dec; 121 Suppl():35-43. PubMed ID: 25434935
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gamma Knife radiosurgery for brain metastases from primary breast cancer.
    Kased N; Binder DK; McDermott MW; Nakamura JL; Huang K; Berger MS; Wara WM; Sneed PK
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1132-40. PubMed ID: 19345514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
    Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
    Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era.
    Karam I; Nichol A; Woods R; Tyldesley S
    Radiat Oncol; 2011 Dec; 6():181. PubMed ID: 22204610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
    Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
    Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
    Kodack DP; Chung E; Yamashita H; Incio J; Duyverman AM; Song Y; Farrar CT; Huang Y; Ager E; Kamoun W; Goel S; Snuderl M; Lussiez A; Hiddingh L; Mahmood S; Tannous BA; Eichler AF; Fukumura D; Engelman JA; Jain RK
    Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3119-27. PubMed ID: 23071298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery.
    Vern-Gross TZ; Lawrence JA; Case LD; McMullen KP; Bourland JD; Metheny-Barlow LJ; Ellis TL; Tatter SB; Shaw EG; Urbanic JJ; Chan MD
    J Neurooncol; 2012 Dec; 110(3):381-8. PubMed ID: 23001361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic grading system specifically for elderly patients with brain metastases after stereotactic radiosurgery: a 2-institution study.
    Yamamoto M; Serizawa T; Higuchi Y; Nagano O; Aiyama H; Koiso T; Watanabe S; Kawabe T; Sato Y; Kasuya H
    J Neurosurg; 2018 Dec; 129(Suppl1):95-102. PubMed ID: 30544299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Brain metastases in breast cancer: analysis of the role of HER2 status and treatment in the outcome of 94 patients.
    Fokas E; Henzel M; Hamm K; Grund S; Engenhart-Cabillic R
    Tumori; 2012 Nov; 98(6):768-74. PubMed ID: 23389365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
    Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
    J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.